<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076036</url>
  </required_header>
  <id_info>
    <org_study_id>Corindus-Corbic-2010</org_study_id>
    <nct_id>NCT01076036</nct_id>
  </id_info>
  <brief_title>CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>CorPath™ 200 System: Coronary Remote Catheterization Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corindus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corindus Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, prospective, single-arm study is designed to evaluate safety, clinical and
      technical efficacy of the CorPath 200 System in delivery and manipulation of the coronary
      guide wires and balloon/stent systems for use in robotically-assisted, percutaneous coronary
      intervention (PCI) procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective The study objective was to evaluate the safety and technical efficacy of the
      CorPath 200 System in delivery and manipulation of commercially available coronary guidewires
      and rapid exchange balloon/stent catheter for use in percutaneous coronary interventions
      (PCI).

      I. Primary Endpoints A. Efficacy Device Clinical Success: Achievement of a &lt; 30% final
      diameter stenosis after utilizing the CorPathTM 200 System to deliver a PTCA balloon and then
      stent to the target lesion, and successfully retract the devices without the occurrence of
      any In-Hospital MACE (Major Adverse Cardiac Event) evaluated at 48 hours post procedure or
      hospital discharge, whichever occurs first.

      B. Safety In-Hospital MACE: Defined as the composite of death (all cause mortality),
      recurrent MI, and target vessel revascularization (emergent coronary artery bypass surgery
      [CABG] or PCI) evaluated at 48 hours post procedure or hospital discharge, whichever occurs
      first.

      II. Secondary Endpoints A. Efficacy CorPath Success: Ability to navigate the guide wire and
      balloon/stent system utilizing the CorPath™ device to the target site without the occurrence
      of any In-Hospital MACE, evaluated at 48 hours post index procedure or hospital discharge,
      whichever occurs first.

      Subject Clinical Success: Achievement of a &lt;30% final diameter stenosis of target lesion
      after treatment with PTCA/coronary stent without the occurrence of any In-Hospital MACE,
      evaluated at 48 hours post-index procedure or hospital discharge, whichever occurs first.

      B. Safety:

      MACE at 30 Days: Defined as the composite of death, recurrent MI and/or target vessel
      revascularization (emergent coronary artery bypass surgery [CABG] or PCI) evaluated at 30
      days post index procedure.

      Adverse Events:

      A summary of all adverse events observed in the trial summarized as either serious or
      non-serious and summarized by attribution.

      C. Clinical Utility

      Procedure Attributes:

        -  Reduction in radiation exposure to the primary operator based on radiation dosimetry
           measurements at the procedure table and on a primary operator.

        -  Total Procedure time based on the time of insertion of hemostasis sheath through the
           time of final guide catheter withdrawal.

      CorPath Device Attributes:

      Subjective assessment by the operator of the following device performance attributes:

        -  Movement of the guide wire (rotating and advancing) to the target.

        -  Maneuvering and position of the guide wire to the target.

        -  Movement of the stent/balloon (advancing) to the target.

        -  Ability to deliver the PTCA/stent system to the intended target lesion.

        -  Ease of use of the system by the interventional team.

      Material &amp; Methods Corindus obtained approval (from the CORBIC Ethics Committee and INVIMA -
      Colombian Ministry of Health) in 2009 to conduct the clinical study &quot;CorPath™ 200 System:
      Coronary Remote Catheterization Feasibility Study&quot; at CORBIC Cardio-Neuro-Vascular Institute,
      Envigado, Colombia.

      The study is a single arm, open label, prospective registry to treat a de novo lesion (2.5 mm
      - 4.0 mm in diameter, 25.0 mm in length with &gt;50% stenosis) utilizing the CorPath 200 System
      to deliver, manipulate and retrieve a guidewire and a balloon/stent catheter system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Procedural Success</measure>
    <time_frame>48-hrs or hospital discharge, whichever occurs first</time_frame>
    <description>The percentage of Participants with &lt;30% final diameter stenosis of the target lesion without in-hospital major adverse cardiovascular events (MACE) (defined as the composite of death, recurrent MI, and target vessel revascularization)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural Technical Success</measure>
    <time_frame>Intervention</time_frame>
    <description>Successful robotic delivery and retraction of all PCI devices during CorPath PCI procedure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CorPath 200 System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Robotic-assisted PCI with the CorPath 200</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorPath 200</intervention_name>
    <description>CorPath™ 200 robotically-assisted percutaneous coronary intervention</description>
    <arm_group_label>CorPath 200 System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorPath 200</intervention_name>
    <description>CorPath PCI - robotic-assisted percutaneous coronary intervention</description>
    <arm_group_label>CorPath 200 System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          -  The subject is an acceptable candidate for PCI.

          -  The subject must have clinical evidence of ischemic heart disease or a positive
             functional study.

          -  Female subjects must be of non-child bearing potential, or if able to bear children,
             have a negative pregnancy test within seven (7) days prior to index procedure.

          -  The subject or the legal representative has been informed of the nature of the study
             and agrees to its provisions and has provided written informed consent.

        Angiographic Inclusion Criteria:

          -  Study lesion is de novo native coronary artery lesion (i.e., a coronary lesion not
             previously treated)

          -  The study lesion is intended to be treated with one stent. Maximum stent length
             allowed is 20 mm.

          -  The study reference vessel diameter is between 2.50 mm and 4.5 mm by visual estimate.

          -  Study lesion diameter showing significant stenosis of at least 50% by visual estimate.

        General Exclusion Criteria:

          -  Subject requires planned PCI or CABG within 30 days following the index procedure.

          -  Subject has evolving ST elevation myocardial infarction (STEMI) (i.e., beginning of MI
             symptoms within 72 hours prior to the planned index procedure).

          -  Subject has documented left ventricular ejection fraction &lt; 30%.

          -  Subject has known hypersensitivity or contraindication to aspirin, heparin,
             ticlopidine, clopidogrel, stainless steel, or a sensitivity to contrast media, which
             cannot be adequately pre-medicated.

          -  Subject has a platelet count &lt; 100,000 cell/mm3 or &gt; 700,000 cell/ mm3, a WBC of &lt;
             3000 cell/ mm3 (e.g. thrombocytopenia, thrombocythemia, neutropenia or leucopenia).

          -  Subject has a history of a stroke (CVA) or TIA within 30-days prior to planned index
             procedure.

          -  Subject has an active peptic ulcer or upper GI bleeding within the 6 months prior to
             planned index procedure.

          -  Subject has a history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions.

          -  Subject is currently participating in another investigational drug l drug or device
             trial that has not completed the entire follow up period.

        Angiographic Exclusion Criteria:

          -  Study lesion that cannot be fully covered by a single stent of maximal length

          -  Subject requires treatment of multiple lesions in the study vessel at the time of
             index procedure.

          -  The study lesion requires planned treatment with DCA, laser, rotational atherectomy,
             or any device except for balloon dilatation prior to stent placement.

          -  The study vessel has evidence of intraluminal thrombus or moderate to severe
             tortuosity (&gt; 90o) proximal to the target lesion.

          -  The study lesion has any of the following characteristics:

               1. Total occlusion

               2. Ostial location

               3. Involves a side branch &gt; 2.0 mm vessel diameter

               4. Is located at &gt;45° bend in the vessel

               5. Is moderately to severely calcified

               6. Moderate-to-severe calcification at the part of the vessel prior to target lesion

          -  Unprotected left main coronary artery disease (an obstruction greater than 50%
             diameter stenosis in the left main coronary artery).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan F Granada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CORBIC and CRF</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CORBIC Cardio-Neuro-Vascular Institute</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2010</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>August 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2015</results_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemia</keyword>
  <keyword>stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>February-March 2011 at CORBIC, Envigado, Colombia</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Group 1 was treated using the CorPath device.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title># of Procedures</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Complete CorPath Procedures</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Didn't meet inclusion/exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Investigational</title>
          <description>CorPath® 200 System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Procedural Success</title>
        <description>The percentage of Participants with &lt;30% final diameter stenosis of the target lesion without in-hospital major adverse cardiovascular events (MACE) (defined as the composite of death, recurrent MI, and target vessel revascularization)</description>
        <time_frame>48-hrs or hospital discharge, whichever occurs first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>CorPath® 200 System</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Procedural Success</title>
          <description>The percentage of Participants with &lt;30% final diameter stenosis of the target lesion without in-hospital major adverse cardiovascular events (MACE) (defined as the composite of death, recurrent MI, and target vessel revascularization)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Procedural Technical Success</title>
        <description>Successful robotic delivery and retraction of all PCI devices during CorPath PCI procedure.</description>
        <time_frame>Intervention</time_frame>
        <population>Total number of PCI devices.</population>
        <group_list>
          <group group_id="O1">
            <title>Investigational</title>
            <description>CorPath® 200 System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Technical Success</title>
          <description>Successful robotic delivery and retraction of all PCI devices during CorPath PCI procedure.</description>
          <population>Total number of PCI devices.</population>
          <units>percentage of PCI devices</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Investigational</title>
          <description>CorPath® 200 System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michail M. Pankratov, MD, PhD, Vice President of Clinical &amp; Regulatory Affairs</name_or_title>
      <organization>Corindus, Inc</organization>
      <phone>508-653-3335 ext 206</phone>
      <email>Michail.Pankratov@Corindus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

